PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
April 24, 2026Rheumatology Advances in Practice1 citationsOpen Access

Management of interstitial lung disease in systemic autoimmune rheumatic diseases: a survey of rheumatologists and pulmonologists

View Full Paper
GBGenna BravermanKAKerri I. AronsonCTCharlene Thomas

Key Points

  • This research assesses the treatment approaches of rheumatologists versus pulmonologists for interstitial lung disease related to systemic autoimmune rheumatic diseases.
  • Cross-sectional survey study conducted in the United States.
  • Participants included rheumatologists and pulmonologists, surveyed electronically through professional societies and social media.
  • Responses analyzed via various statistical methods, including logistic regression and Chi-squared tests.
  • Rheumatologists are less likely to prescribe corticosteroids for asymptomatic and symptomatic ILD compared to pulmonologists (OR 0.14–0.45).
  • Rheumatologists are more inclined to modify immunomodulation strategies for symptomatic and progressive SARD-ILD (OR 1.82–5.44).
  • Distinct differences in treatment decision-making processes were noted between specialties.

Abstract

Abstract Objectives To determine whether rheumatologists and pulmonologists have distinct disciplinary approaches to the management of systemic autoimmune rheumatic disease (SARD)-interstitial lung disease (ILD). Methods This was a cross-sectional survey study of United States rheumatologists and pulmonologists. Surveys were electronically distributed to physicians identified through professional societies and social media. Surveys contained case questions on SARD-ILD management for patients with mixed connective tissue disease, idiopathic inflammatory myopathy, rheumatoid arthritis, systemic sclerosis and Sjogren’s with varying ILD severity (asymptomatic, symptomatic, progressive). Respondents also answered questions on treatment decision-making, comfort with pharmacologic modalities and opinions about interdisciplinary co-management. We analyzed responses submitted 5–9/2024. We compared specialists’ responses via univariate logistic regression, Chi-squared or Fisher’s exact tests; we performed multivariable logistic regression of case questions controlling for practice setting, clinical experience and geographic region. Results Analyses included 309 participants (rheumatologists = 184, pulmonologists = 125). Compared with pulmonologists, rheumatologists were less likely to treat asymptomatic and symptomatic ILD with corticosteroids for all SARD except asymptomatic systemic sclerosis (odds ratios OR 0.14–0.45), and to treat progressive ILD with antifibrotics (OR 0.26–0.30). Conversely, rheumatologists were more likely than pulmonologists to either add or modify immunomodulation/immunosuppression for all symptomatic and progressive SARD-ILD (OR 1.82–5.44). There were disciplinary differences in the relative importance of clinical variables to treatment approaches. Specialists reported ownership over different domains of treatment decision-making and healthcare maintenance. Conclusion This national study suggests distinct disciplinary approaches to management of SARD-ILD, and highlights opportunities to leverage complementary expertise through a co-management paradigm.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Braverman et al. (2026) studied this question.

synapsesocial.com/papers/69eb0a2e553a5433e34b4601https://doi.org/10.1093/rap/rkag050
Ask AI
Helpful
Bookmark
Share
View Full Paper